



Integrating Geriatric Assessments into Routine HIV Care at The THRIVE Program: STRONG & STRIVE

Sarah Schmalzle, MD (Medical Director) Judith Lee, CRNP, AACRN, AAHIVS Institute of Human Virology THRIVE Program/Center for Infectious Disease University of Maryland School of Medicine

Disclosures

- Sarah Schmalzle
 - Gilead HIV Age Positively grant
 - Thera NAFLD advisory board
 - Merck DOR/ISL trial
 - All ended

- Judith Lee
 - Gilead HIV Age Positively grant

- All ended



THRIVE Phase 1 Model: <u>Strengthening Therapeutic Resources for</u> <u>Older adults agiNG with HIV</u>







Model at

the THRIVE program


Together Healing, Reaching, Inspiring, to achieve Victory over illness, and Embrace life

Interprofessional Team

- THRIVE medical director
- THRIVE social work director
- THRIVE pharmacy director
- THRIVE physicians & NPs
 - UMD Gerontologist
 - UMD Epidemiologist
 - UMD AETC lead
 - 2 PhD students

Planning Stage

- Medical literature review
- Consultation with experts
- Patient listening sessions
- Clinician input sessions, needs assessment
- Determination of geriatric assessments to include
 Staff trainings
- Advertisement to patients



Any PLWH >50 at THRIVE self refers

Review results, interventions as necessary





Geriatric Assessments

- Depression, suicidality: PHQ9
- Anxiety: GAD 7
- Cognition: MoCA
- Physical Performance: SPPB
- ADLs: OARS

AidAtlantic

- Frailty: Fried phenotype
- Nutrition: Determine score
- QOL: PROMIS physical & mental

Medical / Pharmacy Chart Review

- HIV: last CD4, HIV RNA
- BMD: DXA
- CVD: ASVCD risk score, ASA and statin use vs. recommendation
- Renal disease: UA, GFR
- Liver disease: LFTs
- Cancer screening: breast, cervical, colon, anal
- Medication reconciliation
- Polypharmacy
- Drug-drug interactions
- Beers list drugs
- Adherence

Social Questionnaire

- HIV history, stigmatization, loss
- Disclosure, support & relationships
- Caregiving & caretaking
- Substance use
- Housing, employment
- Education, finances
- Activities and community
 engagement
- Advanced care planning
- Health care utilization



Adjusting STRONG Model

- Dropped for Phase 2
 - ADLs (redundant)
 - Quality of Life scores (not actionable)
 - Questions (not actionable)
 - First HIV clinic
 - Health care systems/specialties used
 - # pharmacies
 - Support for ADLs

- Added for Phase 2
 - Insomnia screen
 - PTSD screen
 - Hearing test
 - STOPPING aspirin (rather than starting → guidelines changed)
 - Prostate and lung cancer screening
 - NAFLD screening
 - "What Matters Most" questions
 - Vision & dental screen
 - Vaccine review
 - Chewing/swallowing problems



THRIVE Phase 2 Model:

STRENGTHENING THRIVE'S RESILIENT INDIVIDUALS TO LIVE TO 100 CLINIC





NN ARE YOU 50+ YEARS OLD LIVING WITH HIV? NN



STRENGTHENING THRIVE'S RESILIENT INDIVIDUALS TO LIVE TO 100 CLINIC

Goal: To improve health outcomes and your quality of life. Hour-long appointments to comprehensively assess **mind**, **mobility**, **multimorbidity**, **medications** and what **matters most** to you. Exercise, wellness, and nutrition classes will also be available.

(()) MONDAYS FROM 9 AM TO 4 PM (())

(\cdot)	-
\cup	

800 Linden Avenue, 7th floor Baltimore, MD 21201

410-225-8369

NN APPOINTMENT:



111



DO YOU COME TO THRIVE FOR HIV? ARE YOU 50+ YEARS OLD?

AETC AIDS Education & Training Center Pro MidAtlantic

strive to 100 YOGA AND

WEDNESDAYS FROM 2-3PM CONFERENCE CENTER (LOWER LEVEL) UMMC MIDTOWN CAMPUS OUTPATIENT TOWER 800 LINDEN AVENUE, BALTIMORE, MD 21201

WELLNESS

PROGRAM




strive to 100 YOGA AND WELLNESS



Spring Schedule		
3/15	Wellness Walk (Canton Waterfront Park)	
3/22	YOGA	
3/29	Wellness Walk (Canton Waterfront Park)	
4/5	Healthy Eating (snack provided)	
4/12	YOGA	
4/19	YOGA	
4/26	YOGA	
5/3	YOGA	
5/10	Wellness Walk (Canton Waterfront Park)	
5/17	YOGA	
5/24	Wellness Walk (Canton Waterfront Park)	
5/31	YOGA	
All classes will be held on the lower level of the Midtown Outpatient Tower unless otherwise noted in red		

Comprehensive Geriatric Assessment

Comprehensive chart review: patient history, physical examination, questionnaires, labs, medications, etc.





Telemedicine Pharmacy Appointment

- Scheduled 1 week prior to STRIVE appointment
- In-person appointment for "brown bag method"
- Goals:
 - Review current therapy for drug interactions
 - Consider discontinuation of potentially unnecessary therapy
 - Consider adverse drug events as a potential cause for any new symptom(s)
 - Consider safer alternatives, non-pharmacological treatments
 - Ensure appropriate dosing and frequency of all medications
 - Simplify dosing regimens if possible

Medications: Polypharmacy

- The cutoff of 5 medications is consistently associated with negative health outcomes
- Higher chance of drug-drug interactions and adverse effects
 - Beers criteria from the American Geriatrics Society
 - STOPP criteria (Screening Tool of Older Person's Prescriptions)
- Underutilization of beneficial therapy
 - Benefit of statin medications for both primary and secondary prevention
 - ASCVD Risk Scores underestimate risk in PLWH

For the first 100 patients seen at STRIVE:

- Average number of pills: 8
- 29.5% of individuals were prescribed 10 or more medications



Gnjidic D. et al. J Clin Epidemiol 65.9 (2012):989–95 Back D, Marzolini C. J Int AIDS Soc. 2020;23(2):e25449. doi:10.1002/jia2.25449

STRIVE to 100 Visit

- STRIVE to 100 Questionnaire
 - HIV history, stigma, isolation, support system, substance use, housing, access to food, advanced directives, etc.
- DETERMINE Nutrition Screening
 - Disease, Eating poorly, Tooth loss, Economic hardship, Reduced social contact, Multiple medicines, Involuntary weight loss/gain, Needs assistance in self-care, Elder years above age 80
- Insomnia Severity Index (ISI)
- Primary Care PTSD Screen (PC-PTSD)




Matters Most

- "What is your worry or concern about aging?"
- "What does well-being mean to you?"



Matters Most


- "What is your worry or concern about aging?"
- "What does well-being mean to you?"





Mind: Cognition & Mental Health

- Evaluate for memory and/or cognitive changes
 - International HIV dementia scale
 - Montreal Cognitive Assessment (MOCA)
- Social isolation, loneliness, stress and stigma
- Assessments:
 - Patient Health Questionnaire (PHQ-9) for depression
 - General Anxiety Disorder (GAD-7)
 - Insomnia Severity Index
 - Primary Care PTSD Screen for DSM-5 (PC-PTSD-5)
 - 15% positive screening
 - Geriatric Depression scale






Haynes BI, Pitkanen M, Kulasegaram R, et al. HIV Med. 2018;19(6)376-385 Nasreddine ZS, Phillips NA, Bédirian V, et al. J Am Geriatr Soc. 2005;53(4):695-699 Aung HL, Aghivinian M, Gouse H, et al. AIDS Behav. 2021;25(3):917-960

Mobility: Osteoporosis and Frailty

- Higher levels of markers of inflammation and immune activation found in PLWH
- Associations: HIV infection, advanced age, male sex, smoker, chronic HCV infection, depression, and central adiposity
- Screening for osteoporosis with DXA bone density scan recommendations for PLWH:
 - Women post-menopause
 - Men over age 50
- 74.3% of individuals seen for STRIVE were not up to date





AIDS30(2):241-250, January 2016.

Mobility Assessments

- Frailty
 - Fried Frailty Index weight loss, grip strength, walking speed, fatigue, and physical activity
- Physical function
 - Short Physical Performance Battery (SPPB)
 - Gait speed
 - Falls Risk Assessment
- Degree of disability
 - Self-report of daily living and instrumental activities of daily living (OARS Multidimensional Functional Assessment Questionnaire)



Greene M, Justice AC, Covinsky KE. Virulence. 2017;8(5):586-598.

Multicomplexity

Cardiovascular & Pulmonary

- Leading cause of morbidity and mortality in PLWH with a nearly 2-fold increased incidence of cardiovascular events
- Cardiometabolic dysfunction with the use of certain ART such as protease inhibitors
- Screen for tobacco use and counsel on cessation

Renal & Liver

- Exposure to drugs with nephrotoxic potential (such as tenofovir) increases risk for kidney disease
- Rates of co-infection with hepatitis B and C viruses are approximately 25 times higher in PLWH
- Nonalcoholic fatty liver disease has been reported in 30-65% of PLWH

Endocrine & MSK

MidAtlantic

- 4x more likely to have osteoporosis with higher rates of fracture
- Bone density screening recommended for post-menopausal women and men > 50 years old, yet screening rates remain low

Cancer Screenings

- Annual screening for anal cancer and treating/removing abnormal lesions early (ANCHOR study)
- Cervical pap smears should continue after age 65 due to increased risk
- Low-dose CT scan for over 20-pack-year smoking history
- Rates of breast and prostate cancer are comparable to rate in people without HIV

Vaccinations


- HPV vaccine until the age of 45
- Pneumonia vaccine after the age of 65
- Shingles vaccine
- Recommendations include those for the immunocompromised population, including varicella and MMR if CD4 count is ≥200 cells/µL2

Health Maintenance

- Smoking cessation
- Cancer screenings
 - Low dose CT scan for >20 year pack-year history
- Whisper test for hearing
- Dental care
- Eye exams
- Immunizations





Preliminary Findings: Demographics






Preliminary Findings: Demographics








Support System







Recommendations

- Simplifying medication regimen
 - De-prescribing low-dose ASA for primary prevention of CVD in adults 60 years or older according to updated USPSTF guidelines
- NAFLD screening with Fibroscan
- Overdue DEXA and cancer screenings
- Smoking cessation and low-dose CT scan if appropriate
- Initiating or adjusting statin therapy
- Counseling on lifestyle modifications for diet, exercise, and sleep hygiene
- Addressing frailty status and prevention of falls
- Mental health resources, support groups

References

Aung HL, Aghvinian M, Gouse H, et al. Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review. AIDS Behav. 2021;25(3):917-960. doi:10.1007/s10461-020-03053-3

Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23(2):e25449. doi:10.1002/jia2.25449

Brothers TD, Kirkland S, Guaraldi G, et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014;210(8):1170-1179. doi:10.1093/infdis/jiu258

Campos P, Ortiz A, Soto K. HIV and kidney diseases: 35 years of history and consequences. Clin Kidney J. 2016;9(6):772-781. doi:10.1093/ckj/sfw104

Erlandson KM, Karris MY. HIV and Aging: Reconsidering the Approach to Management of Comorbidities. Infect Dis Clin North Am. 2019;33(3):769-786. doi:10.1016/j.idc.2019.04.005

Escota GV, O'Halloran JA, Powderly WG, Presti RM. Understanding mechanisms to promote successful aging in persons living with HIV. Int J Infect Dis. 2018;66:56-64. doi:10.1016/j.ijid.2017.11.010

Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65.9 (2012):989–95

Greene M, Justice AC, Covinsky KE. Assessment of geriatric syndromes and physical function in people living with HIV. Virulence. 2017;8(5):586-598. doi:10.1080/21505594.2016.1245269

Graupera I, Thiele M, Serra-Burriel M, et al. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin Gastroenterol Hepatol. 2022;20(11):2567-2576.e6. doi:10.1016/j.cgh.2021.12.034

Haynes BI, Pitkanen M, Kulasegaram R, et al. HIV: ageing, cognition and neuroimaging at 4-year follow-up. HIV Med. 2018;19(6):376-385. doi:10.1111/hiv.12598

Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis. AIDS Patient Care STDS. 2019;33(3):93-103. doi:10.1089/apc.2018.0190



References

Kooij KW, Wit FW, Schouten J, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls [published correction appears in AIDS. 2016 Jul 17;30(11):1863]. *AIDS*. 2016;30(2):241-250. doi:10.1097/QAD.00000000000910

Martínez-Sanz J, Serrano-Villar S, Vivancos MJ, Rubio R, Moreno S; HIV-associated comorbidities Study Group. Management of Comorbidities in Treated HIV Infection: A Long Way to Go: HIV, comorbidities and aging. Int J Antimicrob Agents. 2022;59(1):106493. doi:10.1016/j.ijantimicag.2021.106493

Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment [published correction appears in J Am Geriatr Soc. 2019 Sep;67(9):1991]. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x

Okeke NL, Chin T, Clement M, Chow SC, Hicks CB. Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. AIDS Care. 2016;28(4):475-482. doi:10.1080/09540121.2015.1099602

Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. Gastroenterol Hepatol (N Y). 2019;15(7):357-365.

Piggott DA, Erlandson KM, Yarasheski KE. Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs. Curr HIV/AIDS Rep. 2016;13(6):340-348. doi:10.1007/s11904-016-0334-8

Proulx J, Ghaly M, Park IW, Borgmann K. HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers. Biomedicines. 2022;10(4):768. Published 2022 Mar 25. doi:10.3390/biomedicines10040768

Pyarali F, Iordanov R, Ebner B, et al. Cardiovascular disease and prevention among people living with HIV in South Florida. Medicine (Baltimore). 2021;100(28):e26631. doi:10.1097/MD.000000000026631

Rabanaque-Hernández MJ. Polypharmacy in older adults with human immunodeficiency virus infection compared with the general population. Clin Interv Aging. 2016;11:1149-1157. Published 2016 Aug 26. doi:10.2147/CIA.S108072

Seth A, Sherman KE. Fatty liver disease in persons with HIV infection. Top Antivir Med. 2019 May;27(2):75-82. PMID: 31136997; PMCID: PMC6550355.

